Advocate Aurora Research Institute, an affiliate of Downers Grove, Ill.-based Advocate Health, is joining Aclarion’s CLARITY clinical trial.
Aclarion is leveraging biomarkers and AI technology to identify the location of chronic low-back pain, according to a May 5 news release.
Aclarion’s Nociscan is the first software-as-service platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine through cloud connection.
Nociscan receives magnetic resonance data from an MRI machine and, through proprietary signal-processing techniques, extracts and quantifies chemical biomarkers associated with disc pain.
The CLARITY trial aims to demonstrate Nociscan’s clinical and economic value in spine surgery. It will enroll 300 patients at high-volume U.S. sites who are scheduled to undergo surgical treatment of 1- or 2-level discogenic low back pain.
The study will be randomized at a 1-to-1 ratio of surgeons blinded-to-Nociscan and unblinded-to-Nociscan to guide the surgical treatment.
Baltimore, Md.-based Johns Hopkins Medicine surgeon Nicholas Theodore, MD, will be the trial’s lead investigator.
